AstraZeneca’s new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month’s supply.
A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer’s Xalkori and Novartis’ Zykadia.
AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group’s growing oncology portfolio.
Help employers find you! Check out all the jobs and post your resume.
